secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001193125-22-281960
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences Q3 2022 net loss $39M; HD trial shows allele-selective mHTT reduction
--------------------------------------------------------------------------------

- Net loss of $39.0M vs $6.2M in Q3 2021; revenue $0.3M down from $36.4M due to Takeda amendment.
- SELECT-HD: WVE-003 reduced mHTT by mean 22% (median 30%) at 85 days post single dose; wtHTT preserved.
- WVE-N531 multidosing underway in DMD; muscle biopsy data expected in 4Q 2022.
- Selected WVE-006 as first RNA editing candidate for AATD; CTA submissions expected in 2023.
- Cash $122.0M as of Sept 30, 2022; runway expected to fund operations to end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312522281960/0001193125-22-281960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312522281960/d366748d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-281960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer